Table 4.
Antibody | Antigen | Description | Clinical status |
---|---|---|---|
IDEC-C2B8 (Rituximab) | CD20 | Chimaeric | FDA approved |
Campath-1H (Alemtuzumab) | CD52 | Chimaeric | FDA approved |
Ofatumumab (HuMax CD20) | CD20 | Humanized | Clinical trials |
Lumiliximab (IDEC-152) | CD23 | Chimaeric | Clinical trials |
Epratuzumab (hLL2) | CD22 | Humanized | Clinical trials |
Hu1D10 (Apolizumab, Remitogen) | 1D10 (HLA-DR β) | Chimaeric | Clinical trials |
CHIR-12.12 | CD40 | Humanized | Clinical trials |